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Major Depressive Disorder (MDD) is a complex, widespread, and recurrent 
psychiatric disorder.  Although the majority of affected individuals respond adequately to 
pharmacotherapy and/or psychotherapy, there persists a sub-population of affected 
individuals who do not improve despite these interventions.  Electric convulsive therapy 
has been described in the research as the most efficacious options for treatment resistant 
depression.  However, due to the neurocognitive deficits associated with ECT, interest in 
transcranial magnetic stimulation (TMS), a non-invasive approach that stimulates the 
cerebral cortex, as an alternative to ECT has become a major research focus.  The 
efficacy of both high-frequency and low-frequency rTMS for depression have been well 
documented although the impact on neurocognitive functioning is not completely 
understood.  Research to date has demonstrated neurocognitive improvement following 
rTMS to the left dorsolateral prefrontal cortex only.  Therefore, this study focused on the 
neurocognitive changes associated with rTMS when administered to the right dorsolateral 
prefrontal cortex and the supplementary motor area, utilizing data from the existing 
EVMS registry for patients receiving TMS.  Measures assessed depression (Beck 
Depression Inventory-II), anxiety (Beck Anxiety Inventory), and neurocognitive 
functioning (CNS-Vital Signs tests of executive function, cognitive flexibility, and 
complex attention).  A series of ANOVAs were conducted to examine: a) whether 
statistically significant differences exist in neurocognitive scores following 2 and/or 6 
weeks of rTMS treatment as compared to pre-treatment; and b) whether any significant 
improvements in neurocognitive scores occur independent of a reduction in depression 
and anxiety scores.  As expected, results revealed statistically significant improvements 
for all three neurocognitive domains across all three time points with the greatest 
improvement taking place during the first two weeks of treatment with a stabilizing effect 
thereafter.  Results also revealed changes in depression and anxiety scores that were not 
significantly correlated with Executive Functioning, Complex Attention, and Cognitive 
Flexibility change scores.  Therefore this study substantiates the use of right-sided, low-
frequency rTMS as a treatment alternative to ECT as it provides support for improved 
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 The primary aim of the present study is to examine possible neurocognitive 
improvements associated with the recommended clinical dose of repetitive Transcranial 
Magnetic Stimulation (rTMS) in the treatment of resistant depression when administered 
to the right dorsolateral prefrontal cortex and supplementary motor cortex.  While 
existing research supports enhanced cognitive functions following left-sided applications 
of rTMS, right-sided applications remain unexplored.  As the efficacy of rTMS for 
treatment resistant depression continues to be established through recent and ongoing 
research, the importance of elucidating its impact on the neurocognitive features 
associated with Major Depressive Disorder (MDD) is paramount.  This is particularly 
true considering the established neurocognitive deficits resulting from the predecessor to 
rTMS, electroconvulsive therapy (ECT).  Therefore, the superiority of rTMS in the 
treatment of refractory depression, not only demands equitable or increased efficacy as 
compared to ECT, but also enhanced neuronal and neuropsychological changes resulting 
from its application.  
 The remainder of this introduction includes a more thorough discussion of the 
rationale for the study along with an overview of both low and high frequency 
Transcranial Magnetic Stimulation (TMS).  The epidemiology and treatment options for 
depression and more specifically, treatment-resistant depression are also addressed.  In 
addition, an overview of the current structural and functional abnormalities and 
neurocognitive deficits associated with depression and the impact of TMS on these 




TMS in the treatment of depression and provide justification for a study of this nature.  
The final section will integrate the preceding sections and provide the final validation for 
this study and the study hypotheses.  
Rationale of the Current Study 
 Major Depressive Disorder (MDD) is not only widespread, but it also tends to be 
recurrent.  In fact, it is among the most prevalent of all psychiatric disorders.  Up to 20% 
of the general population will experience at least one episode of depression throughout 
their lifetime and 80% of those affected will experience a relapse of symptoms.   Despite 
the advancements made possible through neuroimaging as well as through genetic and 
molecular studies, depression remains a complex disorder characterized by vast 
heterogeneity (Gotlib & Hamilton, 2008).  What is more, there persists a considerable 
sub-population of affected individuals who do not improve despite the use of 
psychopharmacological and psychotherapeutic interventions.  It is treatment-resistant 
depression (TRD), with its debilitating nature and high economic cost, that has prompted 
a shift from targeting synaptic transmission for treatment, which fails to completely 
account for depressive symptomology, to a more comprehensive focus on neural circuitry  
(O’Reardon, Peshek, Romero, & Cristancho, 2006).   
 Treatment-resistant depression, a term reserved for a lack of remission despite 
antidepressant treatment in adequate doses (or intensity) and for a time sufficient for 
response, has in large part, driven the research for Transcranial Magnetic Stimulation 
(TMS)  (Fava & Davidson, 1996).  To date, electric convulsive therapy (ECT) has been 
considered the most efficacious treatment for TRD.  ECT is not without its drawbacks 




direct transcranial electrical currents, which requires patients to be anesthetized to ensure 
comfort and to facilitate the administration of muscle relaxation.  Aside from its invasive 
nature and need for sedation, ECT has also been criticized for resulting in cognitive side 
effects.  Specifically, ECT has been shown to produce anterograde amnesia, retrograde 
amnesia and subjective memory complaints (Schulze-Rauschenbach, Harms, Schlaepfer, 
Maier, Falkai, & Wagner, 2005).  For these reasons, interest in TMS, a non-invasive 
approach that stimulates the cerebral cortex, as an alternative to ECT has become a major 
research focus.   
Transcranial magnetic stimulation is not the first use of magnets for healing.  It is 
however unique in its application.  With the use of a pulsed electromagnetic field to 
modulate neuronal activity in the cortex, TMS has been shown to produce antidepressant 
actions.  Some studies have even reported that the efficacy of TMS extends to the 
maintenance treatment of depression (Wang, Xue, Chen, Zhang, Wnag, Yahong, Jingli, 
Zhang, & Qingrong, 2013).  The magnitude and breadth of potential of applicability for 
rTMS for psychiatric and medical patients however is yet unknown.  At present, the FDA 
has approved rTMS for only a marginal sector of the patients.  For its benefits to be more 
fully known and for it to be approved more broadly by the FDA, all risks and benefits 
must be scientifically demonstrated.  Among these are any cognitive benefits and/or 
impairments resulting from rTMS.  This makes research into this inquiry and the 
dissemination of findings to clinicians and patients alike, critical. 
 Like many psychiatric and medical conditions, depression is associated with 
neurocognitive dysfunction.  This has been confirmed not only through subjective reports 




well.  In fact, through these latter techniques, functional and structural abnormalities help 
differentiate individuals with MDD from normals.  They also confirm the need for 
depression subtypes (e.g. symptom-based, aetiologically-based, time of onset, gender 
based, and treatment-resistent) and have helped pave the path for specific and 
individualized treatment options.   
Overview of Transcranial Magnetic Stimulation (TMS) 
 The knowledge that nerves and muscles can be externally stimulated via applied 
electrical currents has long since been established.  In fact, initial experiments date back 
to the 1790s and the work of Galvani and Volta.  The term magnetic stimulation is a bit 
misleading, however, as the magnetic field created during its administration does not 
itself directly stimulate the tissue.  Rather, the magnetic field pulse induces an electrical 
field in the tissue, which causes an ionic current to flow.  If in turn, the amplitude, spatial 
characteristics, and duration of this induction cause depolarization of a nerve membrane, 
then stimulation will occur (Barker & Freeston, 2007).  The earliest application of rTMS 
was used to explore susceptibility to seizure induction following stimulations of the 
motor speed area of the dominant frontal lobe, the area thought to be the most 
epileptogenic area of the brain.  It was through these studies that the added ability of 
rTMS over single-pulse TMS to produce sustained and spatially selective interruptions of 
organized neural activity was discovered.  Repetitive Transcranial Magnetic Stimulation 
(rTMS)  has lead also to the non-invasive mapping of cognitive and perceptual processes 
in the human cortex (Wassermann, 1998).   
 The early 20th century marked the development of magnetic stimulation as a 




the effectiveness of rTMS as a treatment for depressive disorders in particular.  In 2008, 
the United States approved rTMS for clinical use.  Since that time, the interest in the 
therapeutic effects of rTMS on depression among psychiatrists, neurologists, basic 
scientists, and the public at large has surged (Fitzgerald & Daskalakis, 2012).   
 Treatment for depression, using rTMS involves a rapidly timed variable magnetic 
field applied to a localized area of the cortex.  The term repetitive refers to paced 
administration of TMS to a single scalp site.  Although only a restricted area receives 
direct stimulation (with conventional equipment, TMS penetrates no further than 1.5-2cm 
beneath the scalp), distal brain activity is impacted as well (Barker, 1991).  It is through 
the TMS coil that an electrical current is allowed to travel, without resistance, into the 
brain.  When the current passes through the coil, a magnetic field is produced and it is 
this field, when provided above a certain threshold, that ignites electrical activity in the 
underlying cortical neurons.  Over time, with repeated firing, neurons will progressively 
change their activity.  High-frequency stimulation, the most researched TMS application, 
for example, is known to produce an increase in local cortical excitability (Bohning, 
Shastri, McConnell, Nahas, Lorberbaum, Roberts, Teneback, Vincent, & George, 1999).    
The intensity of TMS is usually given as a percentage of the threshold intensity 
for evoking motor evoked potentials (MEPs) of a certain amplitude in a specified fraction 
of a series of consecutive trials in a hand muscle.  Response thresholds to TMS vary 
considerably.  Therefore measures of intensity are formulated on the basis of biological 
efficacy in the individual rather than the output of the stimulator itself.  rTMS dosing is 
determined on an individual bases with the use of an individual’s resting motor threshold 




motor cortex in order to identify the lowest intensity required to consistently induce a 
motor response in a peripheral muscle, usually the abductor pollicis brevis, in the 
contralateral hand.  RMTs are lowest in the muscles of the hand due to the abundance of 
the corticospinal projections that rely on their spinal motor neurons  (Hanajima, Wang, 
Nakatani-Enomoto, Hamada, Terao, Furubayashi, Okabe, Inomata-Terada, Yugeta, 
Rothwell, & Ugawa, 2007).   Antidepressant effects are observed from 90% to 120% of 
the RMT, allowing for intensity reduction if treatment is not being well tolerated.  
However, there does appear to be a relationship between intensity and efficacy, thus, 
reductions should be limited (Loo, McFarquhar, & Mitchell, 2008). 
 TMS is most often administered at a high-frequency to the left dorsolateral 
prefrontal cortex (DLPFC) at between 5 and 20 Hz.  However, other stimulation sites are 
now being targeted for research and clinical application.  Two such sites are the right 
prefrontal cortex and the supplementary motor area, using a low-frequency stimulation.  
Low-frequency refers to stimulus rates of 1 Hz or less.  Where high-frequency TMS 
results in cortical excitability, low-frequency creates the opposite effect (Fitzgerald, 
Fountain, & Daskalakis, 2006).  Although it has not been as extensively researched, TMS 
applied in low-frequencies to the right dorsolateral prefrontal cortex has also been found 
to be efficacious when evaluated alone and equally efficacious when compared to the 
left-sided approach.  Currently, one meta-analysis exists on right-sided treatment and one 
multisite sham controlled trial is being conducted, though no results are yet in print 
(Schutter, 2009).  Advantages of right-sided administration include, less demand on 
equipment and thus fewer concerns about coil overheating, it tends to be better tolerated 




it can be used when high-frequency doses may exacerbate the existing anxiety 
experienced by many depressed patients, when patients have a high RMT or a low 
threshold of tolerance for high-frequency administration, or when there is evidenced 
likelihood of seizure activity (Santiago-Rodriguez, Cardenas-Morales, Harmony, 
Fernandez-Bouzas, Porras, Kattz, & Hernandez, 2008).   
 Regardless of the lateral site, TMS is typically provided five days a week for a 
duration of two to nine weeks.  There are studies currently exploring various treatment-
scheduling options to optimize efficacy and efficiency, but the current recommendations 
suggest that treatment should be provided five times per week unless the patient can only 
attend three to four times per week, which may not undermine efficacy (Turnier, Bruno & 
Pridmore, 2006).  Regarding treatment duration, there is no clear maximum number of 
treatments, but most studies support a minimum of six weeks.  Subtle mood 
improvements are typically expected in the second or third week, but others take longer.  
If improvements are not noted after four weeks of treatment, a change in stimulation site 
or intensity can be considered (Fitzgerald, Benitez, de Castella, Brown, Daskalakis, 
Kulkarni, 2006).  
 Most studies evaluating the efficacy of TMS have involved patients who are not 
on antidepressant medication.  However, there are several trials that have included 
patients on concurrent treatment and patients who began a pharmacotherapy trial at the 
start of TMS treatment.  The findings of these studies did not produce results suggestive 
of benefit over sham.  It has been speculated that this may be due to alterations in RMT 
that interfere with treatment.  For partial responders where medication is maintained 




adjusted accordingly (Herwig, Fallgatter, Hoppner, et al., 2007).   
 By its very nature, depression is a relapsing disorder; treatment responders to 
TMS are no exception.  However, the rate of relapse lends support to the efficacy of the 
long-term benefits of TMS.  For example, in their study including 99 patients who 
received rTMS and were then tracked for 24 weeks, Janicak, Nahas, Lisanby et al., 
(2010) found that only 10 percent of participants relapsed.  For patients who do see a 
recurrence of symptoms, several studies have found results suggesting that most patients 
will respond favorably if treated again using the same treatment parameters (Fitzgerald, 
Benitez, de Castella, Brown, Daskalakis, & Kulkarni, 2006).  Electroconvulsive therapy 
(ECT), on the other hand, is associated with high rates of early relapse.  In a meta-
analysis of relapse rates in responders to an acute course of ECT administered for a major 
depressive episode, Jelovac, Kolshus, and McLoughlin (2013) examined thirty-two 
studies with up to 2 years’ duration of follow-up.  Where pharmacotherapy was continued 
following treatment, 51.1% of patients relapsed by 12 months following successful initial 
treatment with ECT, with the majority (37.7%) relapsing within the first 6 months.  The 
6-month relapse rate was similar in patients treated with continuation ECT (37.2%).  In 
randomized controlled trials, they found that antidepressant medication halved the risk of 
relapse compared with placebo in the first 6 months.  Thus, despite the continuation of 
ECT therapy, the risk of relapse within the first year following ECT is substantial, with 
the period of greatest risk being the first 6 months.  Maintenance of well-being following 
successful ECT undoubtedly need to be improved.  
 Overall, TMS is well tolerated by patients.  In fact, the discontinue rate is much 




For example, in the two large multisite rTMS trials, the drop out rate in the active groups 
were 12% and 10%; single site studies produced drop out rates averaging around 5% 
(O’Reardon et al., 2007; George et al., 2010).  In their meta-analysis examining dropout 
rates in head-to-head medication trials for major depressive disorder, Machado, Iskedian, 
Ruiz, and Einarson (2006) found drop out rates of SNRIs, SSRIs, and TCAs at 26.1%, 
28.4%, and 35.7% respectively.  Side effects are marginal compared with pharmacology 
and include discomfort at the site of stimulation as well as headaches during and shortly 
following treatment.  The risk of these side effects is greatly reduced with guidelines now 
stating that the procedure be prescribed by a physician and that stimulation parameters be 
individually established.  In rare instances, seizures have also been reported.  However, 
not only is the risk of seizure lower for rTMS as compared to ECT, safety studies of 
rTMS have also shown inhibition of the motor cortex after low-frequency stimulation.  
This finding suggests that such stimulation may actually be useful in suppressing the 
development and spread of epileptogenic activity.  Patients who do experience a seizure, 
however, are generally not at an elevated risk of seizure than they were before (George, 
Lisanby, Avery, et al., 2010). 
 Although the overall safety of rTMS is reassuring, there are a few 
contraindications.  For example, individuals with metal in their head, with the exception 
of their mouth, are not good candidates for rTMS due to the potential for metallic 
hardware being heated by the coil.  Clinicians are also cautioned when considering rTMS 
for patients with cardiac pacemakers and implanted medications pumps to consult with 
the manufacturers of such devices.  Compelling clinical reasons would also be necessary 




neuroleptic agents, and other drugs that lower the seizure threshold might be 
contraindications for rTMS.  In each of these circumstances, a conscientious risk-benefit 
assessment must be conducted (Wasserman, 1998).  
Epidemiology of Depression 
 According to the World Health Organization, affective disorders are the most 
debilitating and the most significant contributors to the total burden of disease worldwide 
(World Health Organization, 2001).  The tremendous impact of depression is easily 
explained by its high prevalence, its early onset, its recurrent nature, and the impaired 
social and cognitive capabilities that result, thereby diminishing an individual’s ability to 
adapt to life circumstances and to identify and obtain necessary resources (Miret, Ayuso,-
Mateos, Sanchez-Moreno, & Vieta, 2013).  The burden of depression is not easily 
resolved without efficient health systems and most importantly, available treatment 
strategies.   
 Depression affects an estimated 350 million individuals worldwide.  The rates of 
depression swell during middle-to-late adolescence with gender differences emerging in 
adulthood.  In fact, twice as many women experience depression as men (Hankin and 
Abramson, 2001).  Within the United States, the lifetime prevalence is approximately 
29.9% with a 12-month prevalence of about 8.6%.  Not surprisingly, significant costs to 
patients, their families, caregivers, employers, and insurance payers ensue resulting in an 
estimated cost exceeding $80 billion each year in the United States alone.  These costs, of 
course are associated not only with health care but also with suicide mortality and lost 
workplace productivity (Berry, Broglio, Bunker, Jayewardene, Olin, & Rush, 2013).   




to pharmacotherapy, dispensed at the maximum dose.  An additional 10 to 20 percent will 
improve following additional trials including first or second choice antidepressants.  The 
remaining 10 to 15 percent of patients will not respond to drug therapy and will be 
classified as having treatment-resistant depression.  This designation not only indicates 
that the patient has not experienced a full remission, but has also not seen a 50 percent 
reduction in depressive symptoms (Takahashi, Shirayama, Muneoka, Suzuki, Sato, & 
Hashimoto, 2013).  Not surprisingly, a distinguishing characteristic of this subgroup is 
the common occurrence of suicidal thoughts, attempts, and in up to 10 percent of cases, 
completed suicides, making the discovery of efficacious treatment options critical 
(Ciprani, Girlanda, Agrimi, et al., 2013).  
The primary treatment for TRD is electroconvulsive therapy (ECT).  Due to the 
potential side effects, associated stigma, and unfavorable risk-benefit ratio, many patients 
with TRD will not elect to pursue ECT as a treatment option (Fava & Davidson, 1996).  
The bulk of rTMS research has been conducted with this patient group with outcomes 
suggesting that high-frequency stimulation applied to the DLPFC produced superior 
antidepressant effects compared to sham in numerous meta-analyses, including over 1000 
randomized subjects (Slotema, Blom, Hoek, Sommer, 2010).  
The discussion of TRD would be incomplete without a review of 
psychotherapeutic interventions.  In fact, some have argued that a trial of cognitive-
behavioral therapy by an experienced therapist should be performed before labeling an 
episode of major depression as refractory or treatment resistant.  In support of this 
modification, Fava, Savron, Grandi, and Rafanelli (1997) examined nineteen patients 




and duration who were then treated by cognitive-behavioral methods.  Three of the 
patients dropped out of therapy, but the remaining 16 experienced a significant decrease 
in scores on the Clinical Interview for Depression after therapy.  Twelve patients were 
judged to be in remission at the end of the trial and only one of these patients was found 
to have relapsed at a 2-year follow-up.  Also in support of psychotherapy interventions 
for TRD, Thase, Friedman, and Howland (2001) have suggested that the efficacy of 
pharmacological interventions may be adversely affected by a poor therapeutic alliance, 
low social support, life stress, or chronic adversity and cognitive or personality factors 
such as neuroticism or pessimism.  They review the literature suggesting that 
interpersonal, cognitive, and behavioral forms of psychotherapy have shown to address 
these complexities and should be considered as treatment options when pharmacotherapy 
fails to produce adequate treatment response.  Finally, in their meta-analysis examining 
the treatment of major depression with psychotherapy or psychotherapy-pharmacotherapy 
combinations, Thase, Greenhouse, Frank, et al. (1997) found widespread support for 
combined therapy in more severe, recurrent depressions.  Taken together, it can be argued 
that treatment resistant should apply only when a psychotherapeutic effort has been 
made.  Until then, it may be more appropriate to define depression as “drug refractory” or 
“drug resistant”.  
Neurophysiology/Pathophysiology of Depression 
 Major depressive disorder is a complex, heterogeneous diagnosis characterized by 
a variety of neuroendocrine, neurochemical, neurophysiological, and neuromorphometric 
abnormalities.  Its etiology is related to the interaction of genetics, adverse events in 




Elucidating the interplay among neurotransmitters and the related structural, functional, 
and psychosocial elements has been a major focus of research, especially with the advent 
of neuroimaging (Gotlib & Hamilton, 2008).    
 Initial investigations into the neurobiology of MDD focused almost entirely on 
the monoamine neurotransmitters serotonin (5-HT), norepinephrine (NE) and dopamine 
(DA).  Research into these neurotransmitters resulted in the monoamine hypothesis, 
which has dominated the understanding of depression and driven pharmacological 
approaches to its management.  The hypothesis asserts that depression results from a 
deficiency of monoamines at key sites in the brain (Van Praag, 2001).  The hypothesis 
however is not without its shortcomings.  For example, it cannot account for why two to 
three weeks of pharmacological interventions are required to resolve depressive 
symptoms despite the fact that the monoamine levels targeted by these drugs show 
increases in as few as one to two days.  It also cannot explain the lack of antidepressant 
effects by illicit drugs like cocaine and amphetamine, which enhance these same 
neurotransmitters.  Although most novel antidepressants reflect the claims of the 
monoamine hypothesis, it is being increasingly undermined and new biological models 
for understanding depression are now emerging.  These new approaches have targeted 
dysfunction of the hypothalamic-pituitary-axis, the hypothalamic-pituitary-thyroid, 
second messenger pathways, calcium levels, and cytokines (Hindmarch, 2001).  As the 
knowledge of the brain and depression increases, the increased understanding of these 
and other associated features will likely pave the path for novel antidepressants that 
might be superior to those currently available.  




molecular insights, and the monoamine hypothesis specifically, have been far from 
abandoned.  In fact, Rot, Marije, Mathew, and Charney (2009) have offered a revised 
monoamine hypothesis suggesting that the role of serotonin should continue to be an 
ongoing research emphasis, although a new perspective may be necessary.  For example, 
they assert that the low serotonin synthesis observed in depressed patients might not be 
the cause of depression as traditionally thought but rather, the result of depression and 
that a third variable, responsible for triggering depression, may actually be responsible 
for the reduced synthesis.  
The role of serotonin in depression is also not fully understood without 
incorporating what is known about the genes that influence serotonin metabolism, 
particularly during times of stress.  It cannot be argued that stress is a common 
precipitating factor for depression (Wurtman, 2005).  Although no gene, or even a series 
of genes, have been identified as a cause for depression, the serotonin transporter gene is 
the most studied in MDD.  It is of particular interest to scientists because it contains a 
polymorphism, a gene variation that my increase the risk for depression, that gives rise to 
two different alleles (long and short) that can occur in any combination.  It is the short 
allele that slows down the synthesis of the serotonin transporter, which in turn, inhibits 
the speed that serotonin neurons can adapt to changes in their stimulation.  Therefore, in 
support of a gene-environment interaction, it appears that carriers of the short allele of the 
serotonin transporter may be especially vulnerable to depression when faced with stress 
(Caspi, Sugden, Moffitt, Taylor, Craig, Harrington, McClay, Mill, Martin, Braithwaite, & 
Poulton, 2003).  Other studies have built upon this finding and shown that serotonin is 




example,  Cicchett, Rogosch, Sturge-Apple (2007) examined child maltreatment and 
polymorphisms of the serontonin transporter and monoamine oxidase A (MAOA) genes 
in relation to depressive symptomatology.  Findings did support a gene by environment 
interactions but heightened depressive symptoms were found only among extensively 
maltreated youth with low MAOA activity.  Among comparably maltreated youth with 
high MAOA activity, self-coping strategies related to lower symptoms.  Sexual abuse and 
the 5-HTT short/short genotype predicted higher depression, anxiety, and somatic 
symptoms, but again, this interactions was further moderated by MAOA activity level.  
Therefore, the interactive effects of multiple genes and psychosocial stress on the risk of 
depression will require further research (Cicchett, Rogosch, Sturge-Apple, 2007).   
Norepinephrine, another neurotransmitter driving the monoamine hypothesis, has 
primarily been associated with the experience of stress whereby a threatening or novel 
stimulus evokes an increase in NE activity.  In the context of MDD, depleted NE levels in 
response to prolonged or unresolved stress, dysregulate the mechanisms that would 
typically allow a return to homeostasis following this threat response.  This dysregulation 
has been associated with cognitive symptoms such as hopelessness, helplessness, and 
guilt.  Antidepressants targeting the reuptake of NE specifically have demonstrated 
comparable clinical efficacy to selective serotonin reuptake inhibitors (SSRIs) (Nemeroff, 
Entsuah, Benattia, Demitract, Sloan, & Thase, 2008).   
Like serotonin and norepinephrine, dopamine is another neurotransmitter that is 
thought to play a critical role in the pathophysiology of MDD.  Studies on it function in 
depression have observed that environmental threats perceived by the amygdala raise the 




norepinephrine functioning, inhibitory feedback allows a return to homeostasis following 
a perceived threat.  The possible lack of local inhibitory feedback in the striatal dopamine 
system may help explain why depressed patients often attribute inappropriate salience to 
even mildly negative stimuli (Dunlap & Nemeroff, 2007).  Unlike serotonin and 
norepinephrine, there are currently no antidepressants that directly impact DA 
transmission.  It has therefore been speculated that many patients with MDD might 
experience unremitted or residual symptoms, an especially important consideration when 
exploring treatment-resistant depression.   
  In addition to the molecular aspects of depression, the structural neurology of 
MDD also continues to evolve and guide treatment options.  In fact, there is an entire 
sub-discipline of the biobehavioral sciences dedicated to clarifying the neural bases of 
mood and emotion known as affective neuroscience (Davidson, Pizzagalli, Nitschke, & 
Putnam, 2002).  In response to the advanced neuroimaging techniques now available, key 
regions of the brain implicated in MDD are now being more precisely identified.  
Neuroscientists examining the emotional circuitry of depression have identified some 
consistent findings that point to certain anatomical abnormalities.  Such abnormalities 
have been discovered in the limbic system, a complex of structures including the 
amygdala, hippocampus, subgenual anterior cingulate cortex (ACC), and hypothalamic-
pituitary-adrenal axis.  Cortical areas, namely the dorsolateral prefrontal cortex, also 
appear to play a prominent role in depression, particularly with emotion regulation and 
cognitive control (Davidson, Lewis, Alloy, Amaral, Bush, Cohen, Drevets, Farah, Kagan, 
McClelland, Noel-Hoeksema, & Peterson, 2002).  




attention, assigning emotional significance to stimuli and in remembering emotionally 
significant events (Gotlib & Hamilton, 2008).  Studies have shown that there is an inverse 
relationship between amygdala volume and number of depressive episodes.  Additionally, 
in studies using positron emission tomography (PET), elevated amygdala activity, 
cerebral blood flow (CBF), and metabolism, appear to be positively correlated with 
depressive severity (e.g., Drevets, Bogers, & Raichle, 2002).  Another consistent finding 
suggests the presence of increased amygdala response to emotional stimuli.  This is 
particularly true in response to negatively valenced stimuli (e.g., Sheline, Barch, 
Donnelly, Ollinger, Snyder, & Mintun, 2001).  These patterns, while well documented, 
do not occur in all patients with MDD.  Rather, these trends appear to be more prevalent 
in those who present with a high level of dispositional negative affect and anxiety 
(Davidson, Lewis, Alloy, et al., 2002).  In fact, it has been speculated that the increased 
amygdalar activation in depression in general may also represent a possible biological 
substrate for anxiety, which is often comorbid with depression (Davidson, Pizzagalli, 
Nitschke, & Putnam, 2002).  
 In recent literature, the hippocampus, an area of the brain involved in episodic, 
declarative, contextual, and spatial learning and memory, has also become implicated in 
the expression of depression.  Many forms of psychopathology, depression included, 
involve difficulty in the context-regulation of affect.  In other words, mood and anxiety 
disorders can be characterized by the display of normative affective responses in 
inappropriate contexts.  An example would be sadness that may be appropriate in the 
acute period following a loss but that persists for much longer.  From this, some have 




depression may suggest hippocampal dysfunction.  Recent morphometric studies have 
indeed reported hippocampal atrophy in patients with MDD.  Inconsistencies do exist 
however and may relate to moderator variables that have not yet been identified or the 
possibility that hippocampal atrophy may be a symptom and not a cause of MDD 
(Davidson, Lewis, Alloy, et al., 2002).  
 Another limbic structure, the subgenual ACC is thought to mediate the subjective 
aspects of emotions and emotional responses to stimuli.  Decreases in activity and 
volume for this brain structure are associated with depression (Drevets, Price, Simpson, 
Todd, Reich, Vannier, & Raichle, 1997).   One especially interesting finding, concerning 
from the work of Siegle, Carter and Thase (2006), showed that individuals with 
depression, who respond favorably to cognitive behavioral therapy have less subgenual 
ACC response to affective words than do those who do not improve.   
Other regions of the ACC have also been noted in patients with MDD.  For 
example, it has been postulated that the hypoactivation observed in dorsal regions of the 
ACC in patients with depression might be associated with impaired modulation of 
attention or executive functions and impaired monitoring of competition among various 
response options.  Further, the hypoactivation in ventral regions of the ACC may be 
associated with blunted conscious experience of affect, hypoarousal, anhedonia, reduced 
coping potential in situations characterized by uncertainty and conflict, and expectancy 
violations between the environment and one’s affective state (Davidson, Pizzagalli, 
Nitscheke, Putnam, 2002).  Finally, one study again pointing to the heterogeneity of 
depressive substrates and symptom expression found that a reduction of 




ACC whereas improvements in psychomotor retardation symptoms were associated with 
increased activation in the dorsal ACC (Brody, Saxena, Mandelkern, Fairbanks, Ho, & 
Baxter, 2001).  
 Yet another consistent finding in the research on brain abnormalities in patients 
with MDD involves over-activity of the hypothalamic-pituitary-adrenal (HPA) axis, 
which is responsible for the neuroendocrine response to actual or perceived threats.  In 
fact, it is one of the most replicated biological findings in major depression (Davidson, 
Lewis, Alloy, et al., 2002).  There have been two hypotheses, which are not mutually 
exclusive that been offered as pathophysiological explanations for the HPA over-activity 
noted in depression.  The first one points to the elevated levels of corticotropin-releasing 
factor (CRF) common to depression, stating that these increased levels drive the HPA 
axis into overdrive (Nemeroff, 1996).  The second hypothesis suggests impaired negative 
feedback at both the pituitary corticotrope and central glucocorticoid receptor levels 
(Young, Hasket, Murphy-Weinburg, Watson, Akil, 1991).  
 Cortical structures have also become implicated in depression, namely the 
dorsolateral prefrontal cortex (DLPFC).  The left DLPFC is an area of the brain 
responsible for maintaining the representation of goals and the means to achieve them.  
The right DLPFC however, is hypothesized to be particularly important to the 
maintenance of goals that require behavioral inhibition and withdrawal in situations that 
involve strong alternative response options.  Compared to healthy individuals, studies 
have consistently demonstrated decreased activity during resting state (Mayberg, Lozano, 
Voon, McNeely, Seminowicz, Hamani, Schwalb, & Kennedy, 2005), during relapse 




Malison, Dey, Soufer, & Charney, 1997), and in response to affective stimuli in the 
DLPFC of depressed patients, predominantly on the left side (Hooley, Gruber, Scott, 
Hillner, & Yurgelun-Todd, 2005).  In studies using electroencephalographic (EEG), 
asymmetric activation in anterior scalp regions of the DLPFC has been found showing 
reduced left relative to right activation in depressed and dysphoric individuals (Bell, 
Schwartz, Hardin, Baldwin, & Kline, 1998).  Low levels of activity in the left DLPFC 
would help to explain the tendency for persons with depression to ruminate, reflecting the 
difficulties in cognitive control (e.g., Mayberg, Liotti, Brannan, McGinnis, Mahurin, 
Jerabek, Silva Tekell, Martin, Lancaster, & Fox, 1999).  
The asymmetrical findings in the DLPFC for patients with depression also reveal 
some interesting discoveries specific to the right side.  For example, Debener, Beauducel, 
Nessler, Brocke, Heilmann, & Kayser, (2000) recently confirmed earlier findings of 
greater relative right-sided frontal activation in depressed patients compared with 
controls.  Another related finding suggests that among women in particular, SSRI 
treatment responders had significantly less relative right-sided activation compared with 
non-responders.  Considering the role of right prefrontal regions in components of 
negative affect along with right posterior regions in arousal and anxiety, these findings 
imply that those subjects with global right-activation who would be expected to have 
symptoms of negative affect and anxious arousal are least likely to show improvements 
with SSRI treatment.    
 The picture that emerges from the investigations into the neurobiological aspects 
of depression is one that demonstrates certain trends, but not absolute consistency and 




blood flow (CBF), volume, and glucose metabolism in the aforementioned areas, it is 
important to note that disagreements do exist regarding the specific locations and 
direction of these abnormalities.  And, these structures are all interconnected in regionally 
specific ways, and so, feedback is also bidirectional.  It is therefore still too early to tell 
which of the structural and/or functional abnormalities may be primary and which may be 
secondary.  Depression is above all else, a complex, disorder with multiple subtypes and 
symptom profiles.  Ongoing research will be necessary to more explicitly conceptualize 
depression and the specific neural, functional, and structural abnormalities associated 
with each.  Parsing the heterogeneity of MDD on the basis of known brain circuitry is 
proving to be a promising approach to subtyping that relies more on the objective 
characterization of the specific affective deficits in patients with MDD and less on 
descriptive nosology.  This ambitious effort could lead to the characterization of different 
endophenotypes that could then be used for genetic studies and more tailored treatment 
approaches.   
Neurocognitive Impairments in Depression 
 Along with pervasive mood symptoms and anhedonia, MDD is characterized by 
disturbances in multiple domains including cognition.  In fact, negative thought patterns, 
including pervasive and rigid negative views of the self, the world, and the future are core 
features of depression.  Much like the neurocircuitry of depression however, the specific 
cognitive aspects of depression are not yet fully understood.  What is known, points to 
two main types of cognitive abnormalities in MDD, cognitive biases and cognitive 
deficits, which provide evidence for the potential neurobiological correlates of each 




    Cognitive biases, a particularly common facet of depression, involve directed 
attention and memory towards negative themes in cognitive processing.  Numerous 
studies have demonstrated particular biases primarily related to perception and attention, 
interpretation, and memory.  Regarding perception, depressed individuals show 
preferential perception and processing of information towards negative as compared to 
positive or neutral information (Gotlib and Joorman, 2010).  Similarly, it appears that 
when interpreting information, depressed individuals tend to make stable, global, and 
generally negative inferences for the causes and consequences of life events (Fresco, 
Heimberg, Abramowitz, & Bertram, 2006).  Finally, as it pertains to memory, studies 
have shown that depressed individuals are less able to expel irrelevant negative 
information from working memory than their non-depressed counterparts.  They also 
appear to be more impaired at identifying positive content in the context of 
representations competing for resources in working memory (Levens & Gotlib, 2009).  
Despite these findings, and the gains made in characterizing the negative biases of 
depression, their specific role is far from clear.  And like many other factors associated 
with MDD, the question regarding which is the predecessor, negative biases or depressed 
mood, remains unanswered.  
 Coupled with the research gains made in documenting the aspects of negative 
processing bias in depression, research has also focused on the deficits in cognitive 
functioning unrelated to emotional processing.  Much like the expression of cognitive 
biases, the domains most commonly documented in the literature are attention, executive 
functioning, and memory.  Deficits in these domains are consistently documented and 




E., Jarne-Esparcia, A, et al, 2009).  It is believed that the deficits noted across these two 
groups are due to the reduced metabolic activity within dorsal regions of the prefrontal 
cortex in combination with the elevated limbic activity in MDD (Murrough, Iacoviell, 
Neumeister, Charney, Iosifescu, 2011). 
 Although they are not mutually exclusive and the tasks used to measure cognitive 
domains have considerable overlap, there is enough distinction to discuss them 
separately.  Executive function, which is known to originate in the anterior regions of the 
brain, encompasses judgment, planning, abstract thinking, metacognition, cognitive 
flexibility, inhibition, verbal fluency, initiative, and the ability to direct behavior in a 
goal-directed fashion (Levin, Heller, Mohanty, Herrington, & Miller, 2007).  
Impairments across these facets of executive function have been demonstrated in 
individuals with depression.  Despite this, a clear pattern of impairment with regard to 
subtype of depression, severity, or medication status has not been identified.  This might 
be due to the multiple strategies that can be used to perform these tasks and the 
comorbidity of depression and anxiety (Rogers, Kasai, Koji, Fududa, Iwanami, 
Nakagome, Fukuda, & Kato, 2004).  
 The neural physiology of depression helps bolster what is known about the 
executive functions common in MDD.  The majority of studies have demonstrated that 
elevated activity in a brain region is linked to increased performance on tasks specialized 
to that region (Heller, Kitschke, Etienne, & Miller, 1997).  As already addressed, there is 
an asymmetry of the frontal lobe with decreased activity in the left dorsolateral prefrontal 
cortex.  On a broad level, the left prefrontal cortex appears to be associated with many of 




meaning and generate inferences that extend beyond the information presented, 
strategizing, initiation, and self-cuing (Banich, 2004).  The distinct functions associated 
with the right prefrontal cortex are less understood.  However, preliminary neuroimaging 
has suggested that inhibitory control, the suppression of unwanted memories, and 
involvement in the threat-response network are specialized functions of this region.  
There are a limited number of studies that have specifically investigated the relationship 
between the hyperactivity of the right dorsolateral prefrontal cortex and the regionally 
specialized tasks in MDD.  It has been hypothesized however, that such studies will 
display deficits that correspond with the elevated activity and the specialized tasks 
associated with this region (Nitschke, Heller, & Miller, 2000).  
 Along with impairments in executive function, there are a number of memory 
deficits that have been demonstrated in patients with depression including problems with 
autobiographical remembering, episodic memory recall, and working memory (Levin, 
Heller, Mohanty, Herrington, & Miller, 2007).  The association between depression and 
memory has been identified as quite stable in a meta-analysis examining 147 recall and 
recognition studies in clinically depressed and non-depressed samples.  In this same 
review, two particular findings emerged: deficits with explicit memory tasks were more 
pronounced than implicit tasks and patients with MDD have a propensity to remember 
negative material better than positive material (Burt, Zembar, & Niederehe, 1995).   
 Although memory deficits are well documented in persons with depression, the 
reasons for this trend in depression are a bit less clear.  One hypothesis argues that the 
deficits in executive function may be partly responsible.  Heller and Nitschke (1997) 




initiate the cognitive strategies that enhance an individual’s ability to process and 
remember information.  Another theory has to do with attentional control strategies, 
which are underutilized in person’s with depression.  In studies where these strategies are 
specifically treated through focusing and relevance strategies, memory deficits in 
depression have been observed (Hertel, 1994).  Finally, abilities to efficiently encode 
information and lack of engagement with effortful memory strategies might help to 
explain these particular cognitive deficits.   
 The memory deficits inherent to MDD have also prompted researchers to begin 
investigating the hippocampal abnormalities associated with the disorder.  These studies 
have focused on hippocampal volume however and have not yet targeted how 
hippocampal function is specifically related to cognitive ability.  It is expected however 
that research exploring the intersection of the affective and cognitive aspects of 
subcortical regions will soon ensue (Levin, Heller, Mohanty, Herrington, & Miller, 
2007).  
 Along with deficits in executive function and memory, impaired attention is 
another cardinal feature of depression. In fact, one of the cognitive criteria for the 
diagnosis of depression in the DSM-IV-TR is decreased concentration.  Not only is 
attention a prominent feature of depressive episodes, but problems with sustained 
attention have also been evidenced as an ongoing problem even during periods of 
symptom remission (Weiland-Fiedler, Erickson, Waldeck, Luckenbaugh, Pike, Bonne, 
Charney, & Neumeister, 2004).   
 As with memory, it appears that many of the attentional deficits observed in 




often show an impaired ability to suppress external and internal distractors, which in turn, 
leads to an insufficient allocation of resources.  Evidence for this difficulty in persons 
with depression stems from performance on attentional tasks, which require distractor 
inhibition, such as the color-word Stroop task (Levin, Heller, Mohanty, Herrington, & 
Miller, 2007).  Deficits in attentional processing in depression have also been 
demonstrated with event-related brain potential (ERP) studies.  The results from such 
studies suggest that difficulties with attention are not merely the result of diminished 
motivation (Fernandes et al., 1999; Keller et al., 1999).   
 The cognitive performance associated with depression is yet another reminder of 
its diverse etiologies and manifestations.  Despite the vast number of genetic and 
environmental configurations, depression does appear to affect similar brain regions and 
the functions associated with these cortical and subcortical areas.  Therefore, while the 
discovery of consistent patterns of relationships among specific cognitive impairments 
and specific brain region activity is not yet clear, affective neuroscience is proving that 
continued research efforts are paying off.  With continued exploration into the cognitive 
deficits associated with depression and its various subtypes, the search for respective 
treatment methods that can ameliorate depression becomes more and more promising.  
Effect of TMS on Depression Mechanisms 
 The efficacy of both high-frequency (HF) and low-frequency (LF) rTMS for 
depression have been well documented although the underlying mechanisms are not yet 
fully understood.  The bulk of existing studies have focused on HF application to the left 
dorsolateral prefrontal cortex (DLPFC).  This type of stimulation has been shown to 




more than 1000 randomized subjects (Schutter, 2009; Slotema, Blom, Hoek, et al., 2010). 
 Like HF applications, LF rTMS applied to the right DLPFC and supplemental 
motor area has also been evaluated in a number of trials with promising results.  In fact, it 
has been found to be efficacious when evaluated alone and in all comparative trials, it has 
been shown to share equal antidepressant effects with HF, left-sided treatments 
(Fitzgerald & Daskalakis, 2012).  At present, one meta-analysis exists confirming the 
efficacy of right-sided treatments for depression (Schutter, 2010). 
 The bulk of findings related to the antidepressant mechanisms of rTMS stem from 
animal studies.  Such studies have demonstrated effects of rTMS on dopaminergic 
neurotransmission, a neural substrate of depression previously discussed.  Elevated 
dopamine concentrations have been found in multiple brain regions following both HF 
and LF treatments.  Coupled with increased dopamine, these same studies observed 
increased extracellular glutamate in the same regions (Padberg & George, 2009).  Despite 
this and other studies that have found an effect of rTMS on the neurotransmitter systems 
involved in the pathophysiology of MDD, the comparison to prefrontal rTMS is a bit 
controversial in humans given the functional anatomical differences in men and rodents.  
In a recent study however, Strafella, Paus, Barrett, and Dagher (2001), did observe an 
induction of dopamine release in the caudate nucleus of healthy volunteers following 
rTMS.  
As discussed earlier, two consistent findings reported in the MDD neuroimaging 
literature are the metabolic hypoactivity in the left DLPFC and hyperactivity in the right 
DLPFC, areas, which are interconnected to the brain circuits involved in cognitive and 




stimulating neuronal activity in these brain region will, in turn, exert indirect effects on 
underlying interconnected brain regions and will result in antidepressant effects (Juckel et 
al., 1999).  The DLPFC is anatomically situated on the surface of the cortex, making it a 
highly conductive brain region for exteriorly applied stimulation (the TMS coil is able to 
emit magnetic field pulses through the cranium that remain sufficiently strong for 
approximately 2-3 centimeters deep).  Again, TMS produces an electrical field that 
induces neuronal depolarization that then initiates an action potential.  It is this action 
potential that ignites an excitation of neuronal activity.  “Repetitive” TMS is utilized to 
achieve sustained modulatory effects.  It is this rationale that has been proposed as the 
explanation for the documented antidepressant resulting from rTMS treatment.  However, 
an explanation of the exact mechanism of action driving these effects has not yet been 
completely determined.   
Although cerebral blood flow (CBF) abnormalities are a consistent finding in the 
MDD research, there appears to be an asymmetry in the DLPFC, with reduced flow on 
the left and increased flow on the right.  rTMS addresses this heterogeneity as high-
frequency application enhances cerebral blood flow to the left and low-frequency 
application inhibits cerebral blood flow on the right.  In fact, in their study investigating 
changes in blood flow following low-frequency right prefrontal stimulation (LFRS), Kito, 
Hasegawa, & Koga (2011), found that the therapeutic efficacy of LFRS was correlated 
with decreases in CBF not only in the right prefrontal cortex, but also in the bilateral 
orbitofrontal cortex, right subgenual cingulate cortex, right putamen, and right anterior 
insula.  ECT on the other hand has not been shown to improve upon the cerebral blood 




Moeller, Mukherjee, Schnur, Prudic, and Devanand (1994) found that global and regional 
deficits in cerebral blood flow and glucose metabolism were not reversed by successful 
treatment with ECT.  In fact, in their study, ECT resulted in additional perfusion 
reductions.   
Although the antidepressant efficacy of rTMS for MDD has been repeatedly 
demonstrated, the neuromechanisms implicated in this effect are not fully understood and 
thus, more research is required.  However, for now, there is strong research support for 
the emotional and behavioral consequences associated with its application in patients 
with MDD and what is known about the mechanisms of action for this does parallel the 
known neural substrates of depression. 
TMS and Neurocognitive Changes in Depression 
 The negative impacts on cognitive performance have been the major criticism of 
the treatment methods typically used for depression.  As already discussed, ECT has been 
associated with both subjective and objective memory impairments.  And, even when 
successfully treated with modern antidepressants, patients tend to be better cognitively 
than untreated patients, but they do not perform better than healthy comparison subjects 
(Gualtier, Johnson, & Benedict, 2006).  What makes rTMS so appealing, in addition to its 
proven efficacy for treatment resistant depression, are the number of studies that show 
that in modulating cortical networks, enhancements in cognitive performance result. 
 Cognitive enhancement has been defined as any augmentation of the core 
information processing systems in the brain, including mechanisms underlying 
perception, attention, conceptualization, memory, reasoning, and motor performance 




neurocognitive consequences of TMS and rTMS focused on domains including attention, 
memory, executive functioning, and motor processing.  Across these studies, no adverse 
neurocognitive effects were observed and to the contrary, a trend towards enhanced 
functioning emerged (Bridgers and Delancy, 1998; Hufnagel et al., 1993; Pascual-Leone 
et al., 1993; Wasserman, 1998; Jahanshahi et al., 1997).   
 Studies evaluating the neurocognitive effects of TMS in the treatment of 
depression have produced similar results, despite varying stimulation parameters (Little 
et al., 2000; Speer et al., 2001; Avery et al., 1999; Padberg et al., 1999; Triggs et al., 
1999; Loo et al., 2001).  This is especially promising as the use of rTMS in depressed 
populations typically involves longer exposure and more aggressive stimulation 
parameters and because as compared to healthy volunteers, patients with depression 
typically present with state-dependent cognitive dysfunction (Martis et al., 2003).  As the 
evidence mounts concerning the lack of adverse effects resulting from rTMS treatment, 
the precise neurocognitive changes remain unclear and require additional systematic 
study.  Results of previous research in this area are discussed below. 
 In their study on the cognitive effects of a 10-day trail of both low and high-
frequency rTMS administered to the left PFC, Little et al. (2000) looked specifically at 
verbal learning, memory and fluency abilities.  Results suggested no adverse cognitive 
effects and in fact, demonstrated gains in list recall after one week as compared to 
baseline.  Using similar parameters over a 2-week trail, Speer et al. (2001) also found no 
decrease in scores and a “trend” suggesting improvements in verbal fluency.  In a study 
utilizing 5 session of TMS administered to older adults, Moser et al. (2002) found 




after only 5 days of rTMS, Padberg et al. (1999) demonstrated verbal memory 
improvements using both high and low frequency rTMS to the left PFC.  Using the same 
stimulation site and high frequency (20Hz) rTMS, Triggs et al. (1999) found elevated 
scores on test of executive functioning and attention after 10 days.  Finally, in a study 
using high frequency to the left PFC, Bayan (2013) found significant improvements in 
executive function, complex attention, and cognitive flexibility following 30 days of 
rTMS.  
 In one particularly interesting studying comparing the neurocognitive effects of 
unilateral ECT and rTMS in 30 treatment-resistant depression, Schulze-Rauschenbach et 
al. (2005), produced results favoring rTMS.  Specifically, the rTMS group demonstrated 
improved cognitive performance and subjective memory complaints while the ECT group 
displayed deficits in anterograde and retrograde memory as well as ongoing subjective 
memory complaints.  The incorporation of a healthy volunteer control group helped to 
minimize the potential for practice effects in this study.  
It seems as though the potential adverse effects of rTMS on neurocognitive 
function are benign, and that there may even be some neurocognitive improvement 
resulting from this treatment for MDD, at least for left-sided treatments.  Nevertheless, it 
is vital to continue investigating how different and potentially more effective stimulation 
parameters, including stimulation site, may affect the occurrence of cognitive side effects.  
After considering left-sided treatments from 6 open and 24 controlled studies from 1999 
to 2009, Guse, Faliki, & Wobrock (2010) concluded that certain sub-domains of 
executive functioning seem to exhibit the greatest improvement including working 




treatment parameters across the studies reviewing was lacking, possibly explaining the 
variability across neurocognitive domain improvement in the studies reviewed.  
Furthermore, the vast majority of studies using rTMS have yet to evaluate the impact of 
neurocognitive change following right-sided applications, thereby warranting further 
investigation.   
Study Rationale Conclusions and Hypotheses 
 Depression is a prevalent, disabling, and often, chronic psychiatric condition.  
More than 30% of those affected will not experience remission in response to traditional 
treatments, namely pharmacology.  This treatment-resistant cohort has historically been 
left with limited treatment options.  For this reason, different brain stimulation methods 
have received considerable research attention throughout recent decades.  The oldest of 
these methods, electroconvulsive therapy, is considered an effective antidepressant for 
the acute intervention of treatment-resistant depression.  It is however, invasive, not-
easily tolerated, and has been linked to significant cognitive side effects.  rTMS is now 
emerging as a treatment modality with equal efficacy for treatment resistant depression.  
Unlike ECT however, rTMS is safe, non-invasive, and has been linked with 
neurocognitive improvements.  
 An emerging theme from the literature on the neurobiological aspects of 
depression is the unresolved question regarding the possibility that the cognitive aspects 
of the disorder represent a separate dimension of the illness rather than being attributable 
to the core mood symptoms alone.  Providing support for their distinctness, are the 
longitudinal studies that illustrate a subset of MDD subjects whose cognitive deficits 




executive functioning, even when depressive symptoms have improved (Fava, Graves, 
Benazzi, Scalia, Iosifescu, Alpert, & Papakostas, 2006).  Therefore, it is essential to 
continue the quest to delineate the aspects of depression, particularly the cognitive 
dysfunction that may result in poor psychosocial functioning, and may persist beyond 
certain symptom remission.  Clarity in this regard may justify specific treatment 
strategies aimed at the cognitive and functional deficits in these patients (Murrough et al., 
2011).  rTMS is particularly promising as it’s electromagnetic stimulation of neurons 
capitalizes on neuroplasticity to induce lasting neuronal change within multiple brain 
regions.  Thus, rTMS carries not only the promise of addressing the neural substrates 
responsible for the affective experience of depression, but the possibility of targeting the 
neurobiological basis of the neurocognitive deficits as well.  Preliminary studies have 
begun to provide evidence for this latter possibility, though treatment parameters are 
varied, with many studies utilizing stimulation parameters below what has been 
recommended and have assessed neuropsychological performance with paper and pencil 
tests alone.  In this study, an entire course of treatment was completed using the 
recommended dose of rTMS (35 sessions of 1,200 pulses @ 1Hz, 110% to the RDLPFC 
and 1,200 pulses @ 1 Hz, 100% to the SMA).  The stimulations were delivered in 1-
second pulses each and neuropsychological testing utilized computerized administration, 
enhancing standardization.  This study was also one of the first to investigate the 
neurocognitive changes associated rTMS administration to the RDLPFC and SMA.   
Research Questions 
1. Are there statistically significant differences in neurocognitive scores following 2 




2. If significant improvements in neurocognitive scores are found, do these 
improvements occur independent of a reduction in depression scores? 
Discussion of Possible Outcomes 
 This study aimed to assess the impact of approximately 35 sessions of low-
frequency rTMS on neurocognitive functioning in the treatment of treatment-resistant 
depression.  The current study hypothesized that when low-frequency rTMS was applied 
to the right DLPFC as well as to the supplementary motor area, significant improvements 
in executive functioning, complex attention, and cognitive flexibility scores, as measured 
by CNS Vital Signs (computer-based test battery), from pre-treatment to post-treatment 
would be observed.  Furthermore, it was hypothesized that improvements in 
neurocognitive scores would be evidenced after the initial 2 weeks of treatment with 
continued improvements in scores at post-treatment (Hypothesis 1A).  It was believed, 
based on the findings of previous studies, that improvements would take place 
independent of improvements in clinical depression and anxiety scores, as measured by 
the BDI-II and the BAI (Hypothesis 1B).  Stated differently, neurocognitive score 
improvements would be evidenced independent of mood improvement, suggesting 
mechanisms of change in cognition via neuronal activation in the DLPFC versus 
improvement in mood alone.  If these hypotheses are upheld, it will further validate 
rTMS as a non-invasive and effective treatment alternative to ECT that offers 
neurocognitive benefit versus neurocognitive impairment.  
 In the event that these hypotheses were not upheld, several explanations could 
have been applicable, beginning with methodological limitations.  The very limitations of 




financial, time commitment, unfamiliarity with the treatment, etc.), could have impacted 
the results, leading to non-significant neurocognitive pre- to post-treatment score 
improvements or changes due to small sample size and low statistical power.  These same 
factors may have also caused sample bias and limited the study sample demographic 
(e.g., higher socioeconomic status, higher education levels, older in age).  If however the 
subjects had varied vastly in age, discomfort with the use of computers for the older 
subjects may have led to confounded results.  Another potential restriction was the 
computer-based test battery used in the study, CNS Vital Signs, which may have lacked 
adequate sensitivity to assess the construct of interest (i.e., neurocognitive functioning) in 
a clinical population over time.  Improvements in neurocognition might also have been 
explained by a correlation that exists between improvement in mood scores and 
improvement in neurocognition.  In other words, if results had revealed that 
neurocognitive improvement did not exist independent of mood changes, then it could 
have been expected that a lack of significant change in mood scores would illicit no 
significant change in neurocognition.  A lack of controlled circumstances for subjects 
undergoing rTMS treatment may have also confounded the results.  Such circumstances 
included differences in supplemental treatments for depression (e.g., medications, 
psychotherapy), adherence to the rTMS treatment schedule, severity of depression at 
baseline, and severity of neurocognitive impairment at baseline.  
 It was also possible that if non-significant findings were revealed, it may have 
been due in part to the stimulation parameters themselves.  In the bulk of studies 
illustrating significant improvement in cognitive functions, a left-sided treatment has 




right-sided protocols, which involve two stimulation sites, the right dorsolateral 
prefrontal cortex (RDLPFC) and the supplementary motor area (SMA).  As compared to 
left-sided treatments which typically involve 3,000 pulses administered at 120% of the 
established motor threshold to a single site and a stimulation time of 4 seconds given at 
intervals of 26 seconds, this study included the following: 1,200 pulses @ 1Hz, 110% of 
motor threshold (MT) administered to RDLPFC and 1,200 pulses @ 1Hz, 100% MT 























 Data were derived from a larger study led by Serina Neumann, PhD., Associate 
Professor of Psychiatry and Behavioral Sciences at Eastern Virginia Medial School 
(EVMS).  The study protocol was approved by the Institutional Review Board of EVMS 
on August 24, 2010 (IRB#: 10-07-FB-0135-EVMS).  The purpose of this larger study is 
to establish a registry, or data bank, with information routinely employed in clinical 
practice on patients receiving TMS for the treatment of cognitive, emotional, and 
behavioral disorders (e.g. Major Depressive Disorder, Obsessive Compulsive Disorder, 
and Post Traumatic Stress Disorder) in humans.  These data will serve to elucidate factors 
that may optimize or hinder the effectiveness of TMS in the treatment of these disorders.  
As a part of the broader treatment trial, all patients underwent neurocognitive testing via 
CNS Vital Signs to monitor neurocognitive changes associated with TMS treatment.  
rTMS and TMS treatment eligibility inclusion criteria for participants in the current study 
were as follows: 1) between the ages of 18 and 89; 2)DSM-IV diagnosis of MDD 
(determined by symptom review in the clinical interview and Beck Depression Inventory 
(BDI-II) score of ≥ 16); and 3) failed at least one antidepressant medication trail in the 
past at or above the minimal effective dose and duration in the current episode.  TMS 
treatment eligibility exclusion criteria for participants in the current study were as 
follows: 1) currently suicidal; 2) currently pregnant (as determined via blood test); 3) 
seizure risk: history of seizure disorder, disease or injury that increases seizure risk (e.g. 




trauma), family history of epilepsy, currently on medications that might increase seizure 
risk; 4) implanted electrodes or devices in the body or head; 5) skull defects; 6) tinnitus; 
7) psychotic features; 8) currently taking Wellbutrin and disinclined to discontinue; and 
9) any other contraindications for rTMS.  Along with the clinical interview, medical 
records and clinical measures were reviewed to determine the above inclusion and 
exclusion criteria.  
Procedures 
Recruitment. TMS patients were recruited via referral from various clinicians in 
the surrounding community as well as clinicians within the Eastern Virginia Medical 
School (EVMS) Department of Psychiatry group.  Each referred patient initially 
underwent an initial intake with the study coordinator to screen for any obvious 
contraindications and diagnostic appropriateness.  If patients were determined to be 
eligible, they then underwent two clinical evaluations.   A psychiatrist provided an initial 
interview aimed at evaluating treatment suitability, obtained a brief psychiatric history, 
and gathered a thorough psychiatric medication history.  A licensed psychologist then 
conducted the second evaluation obtaining a more in-depth psychiatric history and 
assessment of symptoms.  Once cleared (i.e., all eligibility criteria outlined in 
Participants section met) and deemed medically appropriate, the frequency and duration 
of treatment for each individual patient was determined by both clinicians and prescribed 
by a board-certified psychiatrist. 
Setting. TMS treatment and assessments take place at EVMS, Psychiatry and 




Administration of treatment and assessments. Once they were deemed eligible 
via clinical evaluations, treatment parameters for individual participants were prescribed 
by a board-certified psychiatrist.  For depression, treatment was prescribed five days per 
week for 6 weeks (approximately 40 minutes per session) and 3 weeks of subsequent 
tapering (e.g., 3 TMS sessions during the 7rd week, 2 during the 8th week, and 1 during 
the 9th week). 
Prior to beginning TMS treatment, clinical and registry consents were discussed 
and signed.  Consent forms that outlined the registry study and TMS treatment purpose, 
procedures, risks, and benefit, were provided to each patient who was then asked to 
indicate their willingness to participate.  Thereafter, patients underwent neurocognitive 
and psychological testing in order to ascertain baseline values.  For the purposes of this 
study, the BDI-II and the BAI were the only psychological assessment measures 
examined.  Neurocognitive functioning was assessed using CNS Vital Signs, a computer-
based neurocognitive assessment battery. Neurocognitive and psychological assessments 
took place at 3 different time points throughout the trial (baseline, 2 weeks after starting 
treatment, and at the end of treatment), with each neurocognitive testing session taking 
approximately 25 to 30 minutes.  
Prior to the initial TMS treatment session, the patient’s resting motor threshold 
was established (RMT).  This ensured precision of stimulation intensity as motor 
threshold can vary depending on factors such as age, gender, and cortical excitability 
(Lisanby, S. H. et al., 2002; Wassermann, E. M., 1998).  RMTs were determined by 
applying a single magnetic pulse over the right motor cortex region, which stimulates a 




a slight twitch in the contralateral thumb was achieved.  The intensity of stimulation was 
set at a maximum of 110% for the RDLPFC and 100 % for the SMA.  Magnetic field 
intensity for each patient’s resting motor threshold was calculated by the NeuroStar 
software.  The coordinates of the resting motor threshold (RMT) and stimulation site, as 
well as the chair positioning parameters, were recorded using a positioning system to 
ensure reliable repositioning upon subsequent treatment sessions.  Once stimulation 
intensity was determined, the exact site of stimulation was located and the coil moved 
accordingly.  The two stimulation sites for this study were the right DLPFC, which is 
located approximately 5 cm anterior to the pre-central gyrus or motor strip, and the 
supplementary motor cortex which is located approximately 2 cm anterior to the pre-
central gyrus or motor strip.  Each treatment session consisted of 1,200 pulses @ 1Hz, 
110% to the RDLPFC and 1,200 pulses @ 1 Hz, 100% to the SMA.  The stimulations 
were delivered in 1-second pulses each.  
Materials 
 
 Beck Depression Inventory-II (BDI-II). For this study depression was assessed 
using the BDI-II (Beck, Steer, & Brown, 1996).  The Beck Depression Inventory-II is the 
most recent revision of a test with more than 35 years of nearly universal use.  It was 
released in 1996 with the purpose of detecting the presence of depression in normal 
populations as well as the severity of depression in diagnosed patients for both adults and 
adolescents over the age of 13 (Arbisi, 1996).  The measure consists of 21 items, each 
item made up of 4 statements organized in increasing severity rated on a 0-3 scale.  The 
summary scores range from 0 to 63, with higher scores indicated higher levels of 




to its ability to assess symptoms that correspond to the criteria listed in the DSM-IV for 
diagnosing depressive disorders.  The psychometric properties of the BDI-II are quite 
good.  Regarding internal consistency, coefficient alpha for the normative samples were 
as follows: outpatient sample = .92; college sample = .93.  This was a notable 
improvement over the BDI-IA, which had an alpha coefficient of .83.  On a related note, 
the test-retest reliability has been reported in the BDI-II at .93 (p < .001) (Beck, Steer, & 
Brown, 1996). 
Beck Anxiety Inventory (BAI). For this study, anxiety was assessed using the 
BAI, which was released in 1988 by Beck, Epstein, Brown, and Steer.  It was designed as 
a measure of anxiety, one of the most common complaints by patients seeking mental 
health treatment.  It is a 21-item self-report measure that was created to assess solely 
anxiety, and not depression.  The BAI was developed using questions from the following 
three measures, all of which were authored or coauthored by Beck: the Anxiety Check 
List (ACL), the Physician’s Desk Reference Check List (PDR), and the Situational 
Anxiety Checklist (SAC).  The 21 questions on the BAI examined the following anxiety 
symptoms: numbness/tingling, hot sensations, wobbly legs, inability to relax, fear of the 
worst, dizziness/lightheadedness, heart pounding, unsteadiness, terrified feelings, 
nervousness, feeling of choking, trembling hands, shakiness, fear of losing control, 
breathing difficulty, fear of dying, feeling scared, indigestion or stomach discomfort, 
feeling faint, flushed face, and sweating (due to something other than heat) (Beck & 
Steer, 1987).  In his Review of the Beck Anxiety Inventory (2010), Dowd praised the 
measure for having excellent internal consistency reliability coefficients (ranges .84 to 




stable over a one-month period (Beck, Epstein, Brown, & Steer, 1988).  Regarding 
content validity, the BAI was created with the DSM-III-R symptom criteria as a 
guideline; mostly notable symptoms of Generalized Anxiety Disorder and Panic Disorder 
were used in this measure.  Concurrent validity correlation coefficients ranged from .51 
to .58 across multiple studies, so Beck and Steer concluded that the correlational 
magnitudes “demonstrate that the BAI is not only significantly but also substantially 
related to other accepted measures of both self-reported and clinically rated anxiety” 
(Beck & Steer, 1987). 
 CNS Vital Signs. CNS Vital Signs, a 30-minute, self-administered, computer-
based battery, was used to assess neurocognitive performance. Studies have produced 
support for strong reliability with test-retest coefficients ranging from 0.65 to 0.88.  
Concurrent validity comparing CNS Vital Signs battery to conventional tests has been 
determined (Gualtieri, Johnson & Benedict, 2006).  In a 2013 study by Bayan, practice 
effects for this battery were explored using non-clinical and clinical samples.  Significant 
improvements in executive function, complex attention, and cognitive flexibility were 
observed in the clinical sample only, suggesting that changes can be attributed to 
treatment factors and not practice effects.     
 Seven conventional neuropsychological tests that span across cognitive domains 
that are sensitive to most causes of cognitive dysfunction and which are known to be 
reliable and valid comprise the CNS Vital Signs battery (Gualtieri & Johnson, 2006).  
These include: Visual Memory (visual learning and memory), Verbal Memory (verbal 
learning and memory), Finger Tapping (motor speed), Symbol Digit Coding (information 




Attention Test (executive function), Continuous Performance Test (sustained attention).  
From these 7 tests, domain scores in the following 10 categories are produced: 
Neurocognition Index (NCI), Composite Memory, Verbal Memory, Visual Memory, 
Processing Speed, Executive Function, Psychomotor Speed, Reaction Time, Complex 
Attention, and Cognitive Flexibility.  
 Because this study aimed to evaluate domain scores for functions associated with 
the prefrontal cortex, only the following were inspected: Executive Function, Cognitive 
Flexibility, and Complex Attention.  With the targeted sites of magnetic stimulation in 
mind, prefrontal cortex functions were hypothesized to be the most robustly affected by 
TMS treatment for depressed patients.  
 Executive Function tests measure one’s ability to recognize rules, categories, and 
manage rapid decision-making.  This predicts how well an individual can sequence tasks, 
multi-task, and track and respond to a set of instructions.  Cognitive Flexibility tests 
capture the ability to adapt to a rapidly changing set of directions that progressively 
increases in complexity.  This ability is relevant to decision-making, reasoning, planning, 
behavioral inhibition, and attentional abilities.  Complex Attention tests measure accurate 
and rapid vigilance as well as the ability to attend and respond to information for an 
extended amount of time.  This ability is relevant to exercising behavioral control.  All 
domain scores are reflected as raw scores, which are then converted to a standard score 
for age (mean score is 100; standard deviation is 15).  
 As already discussed, the tests and test descriptions that form the above aggregate 
domain scores are as follows: 1.) Symbol Digit Coding: serial presentations of screens, 




symbols with empty boxes below.  The test taker is to type in the number that 
corresponds with the symbol that is highlighted, 2.) Stroop Test: comprising of three 
parts: first, pressing the space bar when the word appears on the screen; second, pressing 
the space bar when the color of the word matches the word; third, pressing the space bar 
when the color of the word does not match the word, 3.) Shifting Attention Test: shifting 
from one instruction set to the next quickly and accurately by matching geometric objects 
by color or shape, and 4.) Continuous Performance Test: responding to a target stimulus 
presented on the screen, but not to any other stimulus presented. 
Design and Statistical Analysis 
 For this study, using a Repeated Measures design, the neurocognitive effects of 
TMS in the treatment of depression were evaluated over time.  The repeated measures 
factor was the neurocognitive assessments scores over three different time points (pre-
treatment, 2 weeks, post-treatment) for patients receiving TMS treatment on the RDLPFC 
and SMA for MDD.  An a priori power analysis was conducted to calculate the necessary 
sample size.  For this investigation, the alpha level, or Type 1 error rate, was set to a 
standard .05.  Statistical power was set to .8.  At these specifications, it was determined 
that a sample size of seven would be necessary to detect a Cohen’s d of .25 (partial η2 = 
.577).  Outlined below are the statistical analyses associated with each research question 
listed above: 
1. A. Are there statistically significant differences in neurocognitive scores 
following 2 and/or 6 weeks of rTMS treatment as compared to pre-treatment?  
Three separate analyses were conducted, one for each cognitive domain (i.e., 




repeated measures analysis of variance (ANOVA) comparing pre-treatment, 2 
weeks of treatment, and post-treatment scores.  Pearson correlations were 
conducted to identify statistically significant potential covariates (e.g. BDI-II 
and BAI baseline scores and score change, number of sessions, age, sex, 
education level, and marital status) to be added to each analysis.  Post-hoc 
Tukey’s HSD analyses were used to elucidate any significant differences 
observed. 
 
B. If significant improvements in neurocognitive scores are found, do these 
improvements occur independent of a reduction in depression and anxiety 
scores?  In order to distinguish between neurocognitive changes attributed to 
TMS alone versus changes attributed to clinical improvement, six independent 
correlational analyses were conducted assessing the relationship between 
















 In order to characterize the sample, descriptive statistics were conducted for the 
rTMS treatment group.  Twenty total patients completed a course of rTMS for the 
treatment of treatment-resistant depression.  As seen on Table 1, the total mean age of the 
20 patients was 42.35 with a standard deviation of 12.50 and comprised of primarily 
females (25% males, 75% female) and those of Caucasian background (5% Asian, 5% 
African American, 90% Caucasian).  Patient education level fell between completion of 
general education development (GED) and a master’s degree with the 50% of the sample 
(N=10) achieving a bachelor’s or master’s degree.  All patients met DSM-IV criteria for 
Major Depressive Disorder, with minimum number of years suffering from 
depressive/anxious symptoms being 2 years, maximum number of years being 30 years, 
and a standard deviation of 8.46 years.  Number of rTMS treatment sessions varied 
according to multiple factors including treatment response and insurance allotment.  
Treatment continuation was based on factors assessing clinical response, such as BDI-II 
score decrease, subjective report by the patient, and clinical judgment by the study 










rTMS Group Demographic Data 
 Min Max M SD 
Age 19 59 42.35 12.50 
 











Baseline BAI Score 
 




























 N %   
Gender     
   Male 5 25   
   Female 15 75   
 
Ethnicity 
    
   Caucasian 
   Asian 









    
Marital Status 
    
   Married 11 55   
   Divorced 1 5   
   Separated 0 0   
   Single 8 40   
 
Highest Education 
    
   GED 1 5   
   HS Diploma 3 15   
    Some College 3 15   
   Associate’s Degree 3 15   
   Bachelor’s Degree 9 45   
   Master’s Degree 1 5   
   Doctorate Degree 0 0   
   Professional Degree (MD, JD) 0 0   






Research Question 1 
 
Are there statistically significant differences in neurocognitive scores 
following 2 and/or 6 weeks of rTMS treatment as compared to pre-treatment?  Prior 
to carrying out the research question 1 analyses, Pearson correlations were conducted to 
assess for appropriate covariates to be included in the repeated measures ANOVA 
(baseline, 2 weeks, post treatment).  More specifically, correlations were conducted 
between all potential covariates and each cognitive domain (Executive Functioning, 
Complex Attention, Cognitive Flexibility) at each time point (pre-treatment, 2 weeks, 
post-treatment).  Bi-serial correlations were conducted for all continuous variables (e.g., 
BDI-II and BAI score pre- to post-treatment change, number of sessions, age, baseline 
BDI-II and BAI scores), while categorical and ordinal variables (e.g., sex, education 
level, and marital status) were tested using Spearman’s Rho analyses.  Results, as seen on 
Table 2, did not identify any significant covariates for all three baseline neurocognitive 
domains (i.e., Executive Functioning, Complex Attention, Cognitive Flexibility).  
This research question was examining whether a course of low-frequency, right-
sided rTMS for the treatment of depression leads to changes in neurocognitive scores 
throughout treatment.  CNS Vital Signs was used to assess cognition at pre-treatment, 2 
weeks, and end of treatment.  However, only data for the cognitive domains associated 
with functions implicated by the stimulation site (i.e., DLPFC): Executive Functioning, 
Complex Attention, and Cognitive Flexibility were used to address this research question.  
Three independent, repeated measures ANOVAs (baseline, 2 weeks, post treatment) were 




(Executive Functioning, Complex Attention, Cognitive Flexibility).  All mean scores and 
standard deviations are reported in Table 3. 
The one-way repeated measure ANOVA demonstrated significant improvements 
in executive function, F(1,19)  = 9.76, p = .000, η2p = 0.339.  Post-hoc Tukey’s LSD 
analyses revealed that Executive Functioning mean scores at 2 weeks (102.95  ± 19.63) 
and post-treatment (108.75 ± 12.94) were both significantly greater than pre-treatment 
(88.25 ± 24.71) mean scores (p < .05).  While there was a slight increase in mean score 
from 2 week to post-treatment, this increase however was not statistically significantly 
higher.  Thus, in terms of Executive Functioning performance, significant improvements 
were found after 2 weeks, with those gains remaining stable at post-treatment (Figure 1). 
 Similarly, the second repeated measure ANOVA conducted comparing 
neurocognitive mean scores for Complex Attention, again showed significant 
improvements when all three time points were accounted for, F(1,19)  = 4.798, p = .014, 
η2p = 0.202.  Complex Attention mean scores at 2 weeks (90.25  ± 37.92) and post-
treatment (99.15 ± 10.80) were both significantly greater than pre-treatment (76.55 ± 
40.47) mean scores (p < .05).  Also like Executive Functioning, while there was a slight 
increase in mean score from 2 week to post-treatment, this increase was not statistically 
significant (Figure 2).   
The final repeated measure ANOVA showed Cognitive Flexibility, F(1,19)  = 
10.18, p = .000, η2p = 0.361, also differed significantly across the three time points.  For 
Cognitive Flexibility, post-hoc Tukey’s LSD tests revealed findings mirroring those of 
Executive Functioning and Complex attention with statistically significant increases from 




treatment (106.50 ± 12.58), but no statistically significant increases between 2 week and 
post-treatment (Figure 3).  
 
Table 2 
Pearson Correlations between Potential Covariates and Neurocognitive Domain Scores 
(Executive Functioning, Complex Attention, Cognitive Flexibility) at 3 Time Points (Pre-






























































































































































Sex -.27 -.17 -.13 -.07 -.06 .15 -.25 -.09 -.16 
Marital Status   .19   .16   -.01   .29    .34   .25    .23    .27   -.00 
Education Level   .50*   -.01   .20   .42  -.03   .44   .51*   .08    .26 
          





Means and Standard Deviations at Pre-Treatment, 2 weeks of treatment, and Post-

























































Figure 2.  Complex Attention 3-Time Point Standard Score Means 
 
 
Figure 3.  Cognitive Flexibility 3-Time Point Standard Score Means 
 
 
Research Question 2 
If significant improvements in neurocognitive scores are found, do these 








































This research question examined whether neurocognitive improvements were more 
prominently associated with stimulation of neuronal activity to the DLPFC.  Correlational 
analyses were conducted to examine the relationship between neurocognitive score 
change from pre-treatment to post-treatment and depression and anxiety score change 
from pre-treatment to post-treatment.  Score change was calculated and represented as a 
percentage in which the difference between pre-treatment and post-treatment scores is 
divided by the pre-treatment score.  Six Spearman’s rho correlational analyses were 
conducted assessing the association between each neurocognitive domain (i.e., Executive 
Functioning, Complex Attention, and Cognitive Flexibility) and BDI-II percent change 
score and BAI percent change score.  Results revealed that neither BDI-II nor BAI 
change scores were significantly correlated with Executive Functioning change scores, 
Complex Attention, or Cognitive Flexibility. Correlations are reported on Table 4. 
 
Table 4.  
Correlations between each Neurocognitive Domain Change Score and BDI-II and BAI 
Change Scores Pre- to Post-Treatment 
  
BDI-II (% Change)  
 
BAI (% Change) 
 




























TMS is emerging as a new and effective treatment alternative for the medication 
and psychotherapy resistant population, which continues to demand clarification 
regarding aspects of the treatment that can positively or negatively impact patient 
functioning.  For that reason, exploring the issue of neurocognitive functioning in this 
patient population represents a significant contribution to the TMS and depression 
literature.  
The aim of the present study was to examine whether an experimental, low-
frequency dose of rTMS, which has been shown to contribute to treatment gains for 
treatment-resistant depression in previous research but is not yet FDA approved, leads to 
improvements in neurocognitive test scores from pre-treatment to post-treatment.  This is 
an imperative question to address as current literature only provides evidence of 
neurocognitive change associated with a shorter course of treatment than has been found 
to be the most clinically efficacious for sustained mood improvement or with treatment 
limited to left sided treatment applications (George et al, 2010, O’Reardon et al., 2007, 
Wasserman, 1998, Little et al., 2000; Speer et al., 2001; Avery et al., 1999; Padberg et al., 
1999; Triggs et al., 1999; Loo et al., 2001; Bayan, 2013).  The study further aimed to 
characterize the trajectory of neurocognitive change that occurs throughout the course of 
treatment by examining neurocognitive score differences from pre-treatment to 2 weeks 
to post-treatment.  Specifically, do improvements exist after 2 weeks of treatment, and, if 




have evidenced neurocognitive improvements independent of positive mood changes 
(Vanderhasselt et al., 2009, Rossi et al., 2009), the present study also examined whether 
the evidenced neurocognitive improvements were associated primarily with improvement 
of mood or stimulation of neuronal activity at the targeted treatment site (i.e., DLPFC). 
 Prior studies investigating neurocognitive effects associated with rTMS, have 
offered evidence that rTMS is not associated with adverse neurocognitive effects.   
Rather, previous studies have found improvement, or trends toward improvement, in the 
neurocognitive domains of memory, executive functioning, and motor speed (Little et al., 
2000; Speer et al., 2001; Avery et al., 1999; Padberg et al., 1999; Triggs et al., 1999; Loo 
et al., 2001, Moser et al., 2002, Martis et al., 2003, Schulze-Rauschenbach et al., 2005).  
As previously mentioned, these studies utilized relatively shorter treatment session 
frequencies (e.g., 5 to 15 sessions) than were implemented in the current study (i.e., 35 
sessions) or were limited to left-sided treatments.  However, it is theorized that a longer 
treatment course is more likely to lead to greater, more sustainable effects in 
neurocognition as has been found for treatment of depression with TMS.  Thus, the 
expected outcome was that rTMS would show a significant improvement in 
neurocognitive scores from pre-treatment to post-treatment. 
As expected, results of rTMS neurocognitive score data revealed statistically 
significant improvements for all three neurocognitive domains (i.e., Executive 
Functioning, Complex Attention, and Cognitive Flexibility) across the three time points 
(i.e., pre-treatment, 2 weeks, and post-treatment).  Regarding the differences between the 
three time points (i.e., pre-treatment, 2 weeks, and post-treatment) it was hypothesized 




with continued improvements (or increases) in scores at post-treatment.  However, results 
revealed statistically significant differences across test administrations only when all 
three test administrations were accounted for in the model.  Post-hoc analyses 
demonstrated a pattern of statistically significant improvements in scores from pre-
treatment to 2 weeks.  No statistically or clinically significant improvement or increase 
was found from 2 week to post-treatment for Executive Functioning, Complex Attention, 
and Cognitive Flexibility although scores did increase from 2 weeks to 6 weeks.  
Therefore, in terms of change trajectory overall, based on the present results, it appears 
that the greatest neurocognitive improvement takes place during the first two weeks of 
treatment with a stabilizing (not declining) effect thereafter.  Although the hypothesis that 
a longer treatment course of rTMS will lead to greater neurocognitive improvements was 
not supported, significant improvements in neurocognition were found nonetheless and 
were supported by medium effect sizes.  The observation that cognitive enhancements 
associated with rTMS are predominantly accounted for in the first 2 weeks of treatment is 
consistent with previous findings.  In their systematic review, Guse, Falkai, and Wobrock 
(2009) found that in the majority of studies subjects had 10 stimulation sessions in 2 
weeks. The frequencies ranged from 10 Hz and 20 Hz, the motor threshold between 80 
and 100%.  In consideration of all positive cognitive outcomes, those studies using 
stimulation over a period of 2-4 weeks seem to be most effective.  Two studies, which 
attained significant improving effects with 10-20 Hz, assessed five rTMS sessions only 
(Moser et al., 2002; Triggs et al., 1999).  In two other studies, participants received one 
sham and one real rTMS session (Rektorova et al, 2005; Vanderhasselt et al., 2006).  Five 




amelioration (Boggin et al., 2005; Jorge et al., 2004; Loo et al., 2003; Mosimann et al., 
2004; Rosa et al., 2006).  
Given the evidence that neurocognitive changes appear to take place fairly 
quickly, further implies that neurocognitive change likely takes place independent of 
positive mood changes, or improvements in depression and anxiety scores, since 
abatement of this symptomology requires longer, more consistent stimulation of the 
DLPFC to maintain activity (in this sample 4-6 weeks).  The finding that neurocognitive 
changes take place independent of mood changes was corroborated by Vanderhasselt et 
al. (2009), who in fact did find improved scores on a test of executive functioning after 
only one session of TMS in a depressed sample and no associated clinical improvement.  
The present study further validates this finding and supports the hypothesis that neuronal 
stimulation yields positive effects on neurocognition regardless of improvement in mood. 
Results of the current study revealed changes in depression and anxiety scores that were 
not significantly correlated with Executive Functioning, Complex Attention, and 
Cognitive Flexibility change scores.  This finding demonstrates the functional impact of 
TMS’ role in stimulating neuronal activity in focal regions of the brain implicated with 
particular cognitive functions and may suggest significant implications on the treatment 
of neurocognitive deficits as a result of other neuropsychiatric and neurological illness or 
injuries.  Studies examining changes in cerebral functions following rTMS for a variety 
of diagnoses are available and though findings are inconsistent, many demonstrate 
selective cognitive improvement.  When studying patients with schizophrenia Huber, 
Schneider, and Rollnik (2003) found improvements in psychomotor speed for women 




involving patients with schizophrenia, however, Sachdev, Loo, Mitchell, and Malhi 
(2005) found no significant improvements.  Martis, Alam, Dowd, et al., (2003) found 
improvements in working memory, executive function, objective memory, and fine motor 
speed for patients with bipolar when using 10Hz to the left DLPFC.  Jorge, Robinson, 
Tateno, et al., (2004) observed a trend toward general cognitive improvement in patients 
with post-stroke depression when using 10 Hz to the left DLPFC.   Boggio (2005) 
evidenced a trend toward improvement in executive function when using 15 Hz to the left 
DLPFC in patients with combined Parkinson’s disease and depression.  In patients with 
subjective memory complaints, Sole-Padulles, Bartres-Faz, Clemente, Mollineubevo, et 
al. (2006) demonstrated improvements in associative memory.  Finally, in a study by 
Castel-Lacanal, Tarri, Loubinous, et al. (2014), found that following brain injury, rTMS 
restored the interhemispheric interactions following stroke.  Additional results showed 
improvement in motor recovery, aphasia, and visuospatial neglect.  Taken together, these 
studies are promising but again, because findings are inconsistent, and because the 
pathophysiological and neurobiological basis on these improvements is unclear, 
additional studies including genetics, experimental neurophysiology, and functional brain 
imaging are necessary to explore stimulation-related functional changes in the brain.  
Limitations and Design Considerations  
 One major consideration and limitation of the current study is the small sample 
size.  It was evident that this was a major factor in under-powering potentially significant 
results, particularly for post-hoc analyses.  Patient recruitment and participation is often 
limited and difficult to ascertain due to the continued lack of awareness of this treatment 




Even so, obtaining a larger sample size would enable not only the potential for greater 
power and larger effect sizes, but it would also allow for a more representative sample of 
depressed patients particularly with regard to baseline cognitive functioning.  Sample bias 
is likely to be an issue when sample size is severely limited, in combination with having a 
treatment that is not as accessible to the general public.  Given the high cost of this 
treatment, the sample is liable to consist of individuals of higher socioeconomic status 
(SES).  Thus, a larger and more representative sample would allow for greater statistical 
power and greater generalizability.  
 Another significant limitation relates to the lack of a depressed control group, 
receiving standard treatment and not rTMS treatment, and completing the neurocognitive 
battery at two different time points.  This would allow controlling for possible placebo 
effects associated with receiving rTMS versus no treatment or standard treatment.  
However, the most beneficial and efficacious design would be the randomized-controlled 
trial in which depressed patients are randomized to either a rTMS treatment condition or 
a rTMS sham control condition.  rTMS sham is a control device specially constructed for 
research purposes, more specifically randomized-controlled trials.  It mimics the sound 
and sensation associated with rTMS treatment, without the neuronal stimulation.  Thus, 
both groups go through an identical procedure, which allows for a more powerful method 
of controlling for placebo effects.  
 Participant selection procedures are typically meant to identify a subset of 
depressed patients (i.e., treatment-resistant subset) that allows for greater homogeneity in 
the sample.  However, achieving homogeneity will always pose a major challenge given 




In this particular study, the sample was primarily comprised of Caucasian women with at 
least a high school education.  This of course limits the generalizability of findings. , 
Heterogeneity, as it pertains to depression severity, symptom rate of recovery, treatment 
adherence, and concomitant medication treatment and/or psychotherapy, also poses 
potential confounds that could significantly impact response to rTMS from a 
neurocognitive standpoint.  This could also be greatly controlled for via a randomized-
control study design.  In a randomized-controlled study, the act of randomly assigning 
subjects to either the intervention (receiving TMS treatment) or control (receiving sham 
TMS) group ensures that, on average, no systematic differences (i.e., factors listed above) 
exists between groups and thus outcomes can be seen as attributable solely to the 
intervention.  
Another potential limitation is the battery utilized to assess the specific functions 
implicated with the DLPFC.  While CNS Vital Signs has shown promising reliability and 
validity properties, particularly in its utility for research in a clinical setting (Gualtieri & 
Johnson, 2006), it is possible that more extensive testing of the targeted domains (e.g. 
attention and executive functioning) would provide a more accurate representation of 
each group’s neurocognitive profile.  
Similar to many other rTMS studies, this study was limited by the lack of follow-
up measures.  It is therefore unknown how long the observed effects of rTMS on 
cognitive function will persist.  However, while the duration of the induced cognitive 
effects are lacking, one can assume, based on remaining effects of psychopathology from 
other studies (e.g. improvement of mood), cognitive improvement will persist for a 




A final limitation concerns the positioning of the coil.  This study used the 
Pascual-Leone method whereby the coil was placed 5 cm rostrally from the hot spot of 
the primary motor cortex to identify the DLPFC and 2 cm rostrally to identify the SMA.  
Neuronavigation studies have shown that individual fMRI-guided TMS neuronavigation 
yielded the strongest behavioral effect size as compared to an EEG-system approach and 
the Pascual-Leone method (Sack et al., 2009).  It may therefore stand to reason that 
cognitive changes may be impacted by correct coil positioning.  
The aforementioned limitations demand a careful analysis of the findings and 
interpretations.  First, while no significant changes in cognitive functioning were 
evidenced from 2 weeks to post-treatment, it may be possible that in fact, longer 
treatment does result in greater change, but can only be evidenced by a larger sample size 
or by more precise coil positioning.  At the same time, it is also possible that cognitive 
improvements may be more likely in certain treatment-resistant patient cohorts like those 
represented in this sample and thus, generalizing these findings should be done 
cautiously.  The direct influence of rTMS on cognitive enhancement also should be 
considered thoughtfully due to the number of potential confounds and the possibility of 
placebo effects.  It may also be that because of the close connection and intra-
dependability of the cognitive abilities associated with the frontal cortex, along with the 
psychometric limitations of the tests used to measure them, results only point to general 
cognitive domain improvements and do not specifically delineate between them.  Finally, 
while the cognitive improvements shown in this study are exciting, their durability is not 






The present study was able to contribute to the current empirical knowledge 
maintaining rTMS’ safe and beneficial use for treatment-resistant depression (TRD).  
More specifically, it substantiates the use of right-sided, low-frequency rTMS as a 
treatment alternative to ECT as it preserves cognitive functions.  It extends the existing 
evidence for the ongoing case in making rTMS a first line of treatment for TRD with 
further elucidation of additional rTMS treatment parameter options.  This study also 
provided support for improved functions associated with frontal-lobe functioning: 
executive functioning, attention, and cognitive flexibility.  This is of paramount 
significance as these are functions necessary for optimal functioning and overall well-
being.  
The results of this study also helped to facilitate the understanding of how 
functional processes are actuated by these neurophysiological and neuroplastic changes in 
the brain.  Previous brain imaging studies have demonstrated metabolic and cerebral 
blood flow alterations in the DLPFC, as well as in other limbic, paralimbic, frontal and 
prefrontal regions, after application of rTMS (Kito, Fujita & Koga, 2008, Spear et al., 
2000, Kito et al., 2009).  Furthermore, there has been evidence of grey matter density 
alterations in direct and remote areas of the site of rTMS stimulation after as little as five 
days of treatment, as well as direct evidence of rTMS-induced long-term potentiation in 
humans after a single train of repetitive stimulation (May et al, 2006; Esser et al, 2006). 
This study adds to this by demonstrating a clear pattern of neurocognitive improvements 
that tend to take place sometime during the initial 2 weeks of treatment.  In addition to 




finding that improvements are associated with low frequency rTMS and that they occur 
independent of mood changes, thus likely a direct effect of neuronal stimulation.  This is 
an important contribution to the rTMS literature as it allows for broader treatment 
implications for neurocognitive impairment caused by other injuries or pathologies, such 
as the effects of stroke, TBI, or Parkinson’s.  This opens up the possibility for research to 
investigate the utility of TMS in stimulating underactive or damaged regions of the brain 
identified by MRI, for example, which is also having significant cognitive or functional 
effects on the patient and warranting some form of intervention.  Because the TMS 
effects on cognition are also relatively quick (2 weeks), it also serves as a treatment 
option that is not time consuming or as costly as current rTMS treatment courses for 
neuropsychiatric disorders.  However, with that said, further investigation into the 
durability of cognitive effects, the influence of potential confounds and placebo effects, 
and the generalizability of these findings is still necessary.  This would be ideally 
accomplished with a randomized clinical trail, which includes a sham condition. 
Demonstrating TMS’ capacity for neurocognitive improvement is believed to be a 
substantial finding that can greatly facilitate a much larger and broader role for TMS in 
the field of neuropsychiatry.  However, the provision of evidence of sustainable gains in 
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